FDA Adverse Event Injury Summary report: N

ASR TAP SLV ADAP 11/13 +0

MDR report key: 2801728 · Received October 23, 2012

Report

Report Number
1818910-2012-77042
Event Type
Injury
Date Received
October 23, 2012
Date of Event
November 15, 2011
Report Date
April 27, 2015
Manufacturer
DEPUY INTL., LTD. - 8010379
Product Code
KWA
Removal / Correction Number
Z-1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NZ
Reporter Occupation
PATIENT

Narratives

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. REF. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED. THE CORRECTION/REMOVAL REPORTING NUMBER LISTED APPLIES TO THE CORRESPONDING PRODUCT CODE SOLD DOMESTICALLY.

Additional Manufacturer Narrative · 1

IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE. DEPUY STILL CONSIDERS THIS CASE CLOSED TO CAPA. (B)(4).

Description of Event or Problem · 1

ASR REVISION; ASR XL ACETABULAR SYSTEM (LEFT); REASON FOR REVISION: UNKNOWN.

Description of Event or Problem · 1

NEW ETQ RECORD CREATED IN ORDER TO UPDATE ETQ (LEGACY SYSTEM) COMPLAINT NUMBER (B)(4). REASON FOR ORIGINAL COMPLAINT: ASR REVISION DUE TO TAKE PLACE ON (B)(6) 2011. ASR XL ACETABULAR SYSTEM (LEFT). REASON(S) FOR REVISION: UNKNOWN. UPDATE: ADDED AND AMENDED PRODUCTS. RECEIVED: OCTOBER 5TH 2012. 27 APRIL 2015 - UPDATE - RCVD REASON FOR REVISION: ALVAL, STEM AND STEM SLEEVE DETAILS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ASR TAP SLV ADAP 11/13 +0 HIP FEMORAL STEM/SLEEVE KWA DEPUY INTL., LTD. - 8010379 1861400

Patients

Seq Age Sex Outcome Treatment
1 Required Intervention